^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + LZM-005 (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer
Published date:
12/27/2022
Excerpt:
Here we report a phase I study that evaluated the safety, activity, and biomarkers of LZM005, a HER2 antibody, used as a monotherapy or in combination with trastuzumab plus docetaxel in patients with HER2-positive MBC….In phase Ia, partial response (PR) was achieved in one case (1/14, overall response rate [ORR]: 7.1%); the disease control rate was 42.90% (6/14). In phase Ib, 11 patients (55.0%) achieved PR, and eight (40.0%) had stable disease. The ORR was 100% (6/6) in trastuzumab-naive and 35.7% (5/14) in trastuzumab-pretreated patients.
Secondary therapy:
docetaxel
DOI:
10.1038/s41523-022-00501-2
